Under the agreement, Emergent will help with services involving development and analytical testing and will reserve some of its large-scale manufacturing capacity through 2020 for the vaccine.
Emergent BioSolutions Inc said on Thursday it signed a $87 million deal to make AstraZeneca Plc's experimental COVID-19 vaccine in the United States, as the British drugmaker looks to ramp up its efforts to bring a vaccine to the market.
Under the agreement, Emergent will help with services involving development and analytical testing and will reserve some of its large-scale manufacturing capacity through 2020 for the vaccine.
Comments
0 comment